Pharmaceutical Combination of Oral Ivermectin and Mebendazole for Treatment of Refractory or Metastatic Pancreatic Cancers

Abstract

This invention introduces a fixed-dose oral pharmaceutical combination of ivermectin and fenbendazole, and/or mebendazole, designed as a last-line therapy for patients with advanced, metastatic, or treatment-resistant disease. It is particularly intended for use in terminal-stage cancers—including solid tumors and hematologic malignancies—as well as immune-mediated inflammatory conditions and rare disorders. This standardized formulation, available in tablet, capsule, or oral liquid form, ensures consistent bioavailability. By repurposing well-established anthelmintic agents with documented safety profiles, this therapy engages broad-spectrum, multi-mechanistic actions to overcome tumor progression, drug resistance, chronic inflammation, and immune dysregulation across diverse disease categories, and is supported by 84 peer-reviewed mechanistic and early-clinical/preclinical studies, including 18 published in Nature-family journals, and 239 real-world clinical observations. These three repurposed agents collectively act through more than seventy-eight validated mechanisms, operating individually and in overlapping synergistic pathways, thereby establishing a robust scientific and clinical foundation for its use.